Krähenbühl S, Raisin J, Herren T
Medizinische Klinik, Universität Bern, Inselspital Bern.
Schweiz Med Wochenschr. 1993 Jul 3;123(26):1359-62.
A patient with myeloma nephropathy and acute, probably diclofenac-induced renal failure developed a neuroleptic malignant syndrome (NMS) during treatment with metoclopramide and neuroleptics. These drugs were withdrawn, symptomatic treatment of NMS was started and the patient was hemodialyzed because of uremia. During hemodialysis, the patient's condition improved dramatically and NMS did not recur during her further stay in the hospital. The temporal relationship between metoclopramide administration and the development of NMS, as well as the rapid reversal of NMS, suggest that NMS in this patient was caused by metoclopramide and not by neuroleptic drugs. Thus, metoclopramide should be used with caution in patients with renal failure and patients should be monitored closely for the development of neuroleptic malignant syndrome. Hemodialysis may be therapeutically effective in certain patients with metoclopramide-induced NMS.
一名患有骨髓瘤肾病且急性肾衰竭(可能由双氯芬酸引起)的患者,在接受甲氧氯普胺和抗精神病药物治疗期间发生了抗精神病药恶性综合征(NMS)。停用了这些药物,开始对NMS进行对症治疗,并且由于尿毒症对患者进行了血液透析。在血液透析期间,患者的病情显著改善,在其住院的剩余时间里NMS未复发。甲氧氯普胺给药与NMS发生之间的时间关系,以及NMS的迅速缓解,提示该患者的NMS是由甲氧氯普胺而非抗精神病药物引起的。因此,肾衰竭患者应谨慎使用甲氧氯普胺,并且应密切监测患者是否发生抗精神病药恶性综合征。血液透析对某些甲氧氯普胺诱导的NMS患者可能具有治疗效果。